Literature DB >> 26954291

Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization.

Dan Chen1,2, Jianxuan Zou1,2,3, Yunhui Zong1,2,4, Huimin Meng1,2, Gangli An1,2, Lin Yang1,2,5.   

Abstract

Syndecan-1 (CD138), a heparan sulfate proteoglycan, acts as a co-receptor for growth factors and chemokines and is a molecular marker associated with the epithelial-mesenchymal transition during development and carcinogenesis. In this study, we generated two specific mouse anti-human CD138 monoclonal antibodies (mAbs, clone ID: 480CT5.4.3, 587CT7.3.6.5) using hybridoma technology and identified their immunological characteristics. After hybridoma sequencing, the single-chain variable fragments (ScFvs) cloned from two hybridoma cells were combined with anti-CD3 OKT-3 ScFv to generate two recombinant bispecific antibodies (h-STL002, m-STL002) against CD138 and CD3 molecules, respectively. The bispecific antibodies were able to specifically target CD138 + multiple myeloma (MM) cells and CD3 + T cells, and showed the potent cytotoxicity against MM RPMI-8226 cell line through T cell activation. However, these bispecific antibodies without T cells did not cause toxic side effect on MM cells. Overall, the two hybridoma clones and their bispecific formats have great potential to promote diagnosis and immunotherapy of plasma cell malignancy.

Entities:  

Keywords:  Bispecific antibodies; ScFv; T cells; multiple myeloma; syndecan-1

Mesh:

Substances:

Year:  2016        PMID: 26954291     DOI: 10.3109/08923973.2016.1153110

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  6 in total

Review 1.  Bispecific Antibodies in Multiple Myeloma: Present and Future.

Authors:  Guido Lancman; Dahniel L Sastow; Hearn J Cho; Sundar Jagannath; Deepu Madduri; Samir S Parekh; Shambavi Richard; Joshua Richter; Larysa Sanchez; Ajai Chari
Journal:  Blood Cancer Discov       Date:  2021-08-17

Review 2.  Targeting syndecan-1: new opportunities in cancer therapy.

Authors:  Zecheng Yang; Shuaitong Chen; Haoqiang Ying; Wantong Yao
Journal:  Am J Physiol Cell Physiol       Date:  2022-05-18       Impact factor: 5.282

3.  Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.

Authors:  Ying Chen; Fengtao You; Licui Jiang; Jialu Li; Xuejun Zhu; Yangyi Bao; Xiang Sun; Xiaowen Tang; Huimin Meng; Gangli An; Bozhen Zhang; Lin Yang
Journal:  Oncotarget       Date:  2017-06-06

4.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.

Authors:  Nina Shah; Jack Aiello; David E Avigan; Jesus G Berdeja; Ivan M Borrello; Ajai Chari; Adam D Cohen; Karthik Ganapathi; Lissa Gray; Damian Green; Amrita Krishnan; Yi Lin; Elisabet Manasanch; Nikhil C Munshi; Ajay K Nooka; Aaron P Rapoport; Eric L Smith; Ravi Vij; Madhav Dhodapkar
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

5.  IL22 furthers malignant transformation of rat mesenchymal stem cells, possibly in association with IL22RA1/STAT3 signaling.

Authors:  Xiangrong Cui; Xuan Jing; Qin Yi; Zhongping Xiang; Jie Tian; Bin Tan; Jing Zhu
Journal:  Oncol Rep       Date:  2019-02-11       Impact factor: 3.906

6.  Clinicopathological and prognostic significance of SDC1 overexpression in breast cancer.

Authors:  Xiangrong Cui; Xuan Jing; Qin Yi; Chunlan Long; Jie Tian; Jing Zhu
Journal:  Oncotarget       Date:  2017-11-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.